In Q2 2024, Tang Capital Management held 96 positions worth $830.0M. They initiated 27 new positions and exited 50. Their largest holding was TARS ($61.3M). Portfolio value grew +6.7% versus the prior quarter.
Frequently asked questions
What stocks did Tang Capital Management own in Q2 2024?
Tang Capital Management held 96 biotech stocks in their 13F portfolio in Q2 2024. Their top positions include TARS, EOLS, KALV, MIRM, ANAB. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Tang Capital Management's portfolio worth in Q2 2024?
Tang Capital Management's tracked biotech portfolio was worth $830.0M across 96 positions, with total assets under management of approximately $2B. Portfolio values are based on 13F filings with the SEC.
What did Tang Capital Management buy in Q2 2024?
Tang Capital Management initiated 27 new positions in Q2 2024, including JAZZ, TDOC, BIIB, REPL, DEI and 22 more. They also increased 35 existing positions.
What did Tang Capital Management sell in Q2 2024?
Tang Capital Management fully exited 50 positions in Q2 2024, including SCYX, RXDX, ITOS, TIL, FHN-PH and 45 more. They also trimmed 2 existing positions.
Is Tang Capital Management a biotech fund?
Event-driven biotech specialist known for concentrated bets around clinical catalysts, M&A situations, and activist campaigns. Deep industry relationships and willingness to engage publicly make the fund a closely watched market signal.
Want AI analysis, insider signals, and catalyst overlays for Tang Capital Management?
View latest Tang Capital Management portfolio →